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2Abstract
Purpose: Aminopeptidase N (APN/CD13) plays an important role in tumor neoangiogenic
process and the development of metastases. Furthermore, it may serve as a potential target for
cancer diagnosis and therapy. Previous studies have already shown that asparagine-glycine-
arginine (NGR) peptides specifically bind to APN/CD13. The aim of the study was to
synthesize and investigate the APN/CD13 specificity of a novel 68Ga-labeled NOTA-c(NGR)
molecule in vivo using miniPET.
Methods: c[KNGRE]-NH2 peptide was conjugated with p-SCN-Bn-NOTA and was labeled
with Ga-68 (68Ga-NOTA-c(NGR)). Orthotopic and heterotopic transplanted mesoblastic
nephroma (NeDe) bearing Fischer-344 rats were prepared, on which biodistribution studies
and miniPET scans were performed for both 68Ga-NOTA-c(NGR) and αβ3 integrin selective
68Ga-NODAGA-[c(RGD)]2 tracers. APN/CD13 receptor expression of NeDe tumors and
metastases was analyzed by western blot.
Results: 68Ga-NOTA-c(NGR) was produced with high specific activity (5.13-5.92 GBq/µmol)
and with excellent radiochemical purity (95%<), at all cases. Biodistribution studies in normal
rats showed that uptake of the 68Ga-NOTA-c(NGR) was significantly (p0.05) lower in
abdominal organs in comparison with 68Ga-NODAGA-[c(RGD)]2. Both radiotracers were
mainly excreted from the kidney. In NeDe tumor bearing rats higher 68Ga-NOTA-c(NGR)
accumulation was found in the tumors than that of the 68Ga-NODAGA-[c(RGD)]2. Using
orthotopic transplantation, metastases were developed which showed specific 68Ga-NOTA-
c(NGR) uptake. Western blot analysis confirmed the presence of APN/CD13 expression in
NeDe tumors and metastases.
Conclusion: Our novel radiotracer 68Ga-NOTA-c(NGR) showed specific binding to the
APN/CD13 expressed ortho- and heterotopic transplanted NeDe tumors. Therefore, 68Ga-
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NODAGA 1,4,7-triazacyclononane-1-glutaric acid-4,7-acetic acid
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid
RGD argininyl-glycinyl-aspartic acid
PET positron emission tomography
RCP radiochemical purity




4Chemical compounds studied in this article:
L-Arginine CID: 6322
L-Asparagine CID: 6267
(benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate CID 151348
N-diisopropylethylamine (DIEA) CID 81531
dimethylformamide (DMF) CID 6228
L-Glutamic acid CID: 33032
Glyicine CID: 750
1-hydroxybenzotriazole (HOBt) CID 2796029
L-Lysine CID: 5962
1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) CID 3036142
triflouroacetic acid (TFA) CID 6422
triisopropylsilane (TIS) CID 6327611
51. Introduction
Angiogenesis, the formation of new blood vessels from pre-existing vasculature is a
fundamental physiological process (Simons 2005); nevertheless this process might be
triggered and enhanced by many human diseases including cancer (Folkman 2002),
congestive heart failure (Higuchi et al., 2008) , atherosclerotic plaque and peripheral artery
disease (Carmeliet and Jain 2000; Wu et al., 2013). Numerous studies also suggest that tumor-
vasculature formation is followed by a characteristic sequence of events, mediated and
controlled by growth factors, adhesion molecules, and cellular receptors (Ellis et al., 2001;
Yancopoulos et al., 2000), which can serve as a biochemical platform for targeted tumor
diagnosis and therapy (Haubner et al., 1999, 2001; Wang et al., 2011; Dijkgraaf et al., 2013).
Related to this process, two important targets have already been revealed on the new tumor
vasculatures; integrins (Ellis et al., 2001; Seong Choe et al., 2007; Haubner, 2006) and
Aminopeptidase N (APN or CD13) (Pasqualini et al., 2000; Corti et al., 2008). The latter is a
zinc-dependent, trans-membrane exopeptidase that also plays an important role in metastatic
tumor cell invasion through enzyme-catalyzed degradation of extracellular matrix components
(Rundhaug 2005). Furthermore, high expression of CD13 can be detected in a number of
human solid tumors, including melanoma (van Hensbergen et al., 2004), prostate, lung and
ovarian cancer (Chen et al., 2013).
An asparaginyl-glycinyl-arginine (NGR) sequence containing peptides have been identified
via phage display as specific ligands of CD13 (Corti et al., 2008). Also, it was found to bear a
threefold higher efficacy for the detection of neoangiogenic vessels than RGD (argininyl-
glycinyl-aspartic acid) peptides (Buehler et al., 2006) that are widely used for the detection of
ανβ3 and ανβ5 integrin-expression. As such, several studies have reported that the conjugation
of an NGR motif with chemotherapeutic drugs might lead to improved and more specific
tumor-therapy (Arap et al., 1998; Corti and Curnis 2011; Corti et al., 2011; Curnis et al.,
2000) or the labeling of such derivative with 64Cu (Chen et al., 2013) or 68Ga (Zhang et al.,
2014; Shao et al., 2014a) (PET-imaging) or with 99mTc (Ma et al., 2013; Ma et al., 2014)
(SPECT-imaging) can serve as useful radiotracers for the in vivo imaging of CD13-expression
of tumors and neovasculature by binding to APN. Moreover, NGR based radioligands beside
the diagnostic purpose might also make it feasible to monitor a tumor’s response to therapy,
which is important to follow the efficacy of the treatment.
Among in vivo, functional imaging techniques, Positron Emission Tomography is one of the
most sophisticated methods that also makes it possible to detect tumors with high accuracy
6and sensitivity followed by easy quantification (Wester 2007). Furthermore, PET-isotope, Ga-
68 bears close to ideal physical properties (89% β+; t1/2 = 67.7 min; Eav(β+) = 740 keV), easy,
on-site accessibility via 68Ge/68Ga-generators and offers a well-established complexation
chemistry for the labeling of biomolecules (Velikyan 2013; Smith et al., 2013; Banerjee and
Pomper 2013). To our knowledge, only a few 68Ga-labeled NGR conjugates were evaluated
under preclinical circumstances for CD13-expression-imaging (Zhang et al., 2014; Shao et al.,
2014b). As it has been shown that the cyclic form of NGR has approximately ten-fold greater
targeting efficacy than linear configurations of the same peptide sequence for targeting
different tumors (Colombo et al., 2002), a cyclic NGR motif containing radiotracer might lead
to high diagnostic efficiency. On the other hand, in order to create a 68Ga-labeled c(NGR)
conjugate a chelator other than DOTA with the ability to efficiently chelate trivalent gallium-
ion at room temperature must be chosen, as thermal stability of a DOTA-c(NGR) conjugate
might be insufficient due to decomposition of the cycle or the elevated temperature can
enhance the conversion of asparagine residue into isoaspartate and aspartate resulting in
isoDGR and DGR sequence (Curnis et al., 2008).
In present study, we intended to combine the advantages of the high affinity of cyclic NGR
peptide with simple, room-temperature 68Ga-labeling of 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) to create a highly specific radiotracer for the detection of CD13-
positive tumors. For homing devices, c[KNGRE]-NH2 (cyclic(lysine-asparagine-glycine-
arginine-glutamic acid amide)) cyclic peptide (Negussie et al., 2010) was selected in this
study because of its significantly higher stability against deamidation compared to cyclic
NGR peptides with disulfide bridge. (The comparison of stability of cyclic NGR peptides will
be published in a following study). In addition, PET-imaging properties of the new tracer
were compared to commercially available, 68Ga-labeled NODAGA-RGD dimer acetate on the
very same syngenic, rat tumor models (Trencsenyi et al., 2009; Rozsa et al., 2009) with the
potential of showing these tracers capability for metastasis detection in order to further test
the utility of 68Ga-NOTA-c(NGR).
72. Materials and Methods
2.1. Chemicals
All commercially available chemicals were of analytical grade and used without further
purification. All amino acid derivatives for peptide synthesis were purchased from Reanal
(Budapest, Hungary) and IRIS Biotech GmbH (Marktredwitz, Germany), while solvents for
synthesis and purification were obtained from Molar Chemicals Kft (Budapest, Hungary).
For the radiolabeling studies, Ultrapur® water, HCl and NaOH were obtained from Merck. All
other chemicals were the product of Sigma-Aldrich Co. (St. Louis, MO, USA), if not
specifically stated otherwise.
2.2. Synthesis of c[KNGRE]-NH2 cyclic peptide with amide bond
Linear semi-protected H-Lys(ClZ)-Asn-Gly-Arg-Glu-NH2 was prepared manually by
Fmoc/tBu strategy on Rink-Amide MBHA resin (0.52 mmol/g capacity). Standard Fmoc-
amino acid derivatives were used for the synthesis except Boc-Lys(ClZ)-OH that was
attached to the N-terminus of the peptide. The semi-protected peptide was cleaved from the
resin using a mixture of 95 % TFA, 2.5 % TIS and 2.5 % water (v/v/v) for 3 h at room
temperature and then precipitated and washed three times with ice-cold diethyl ether. The
product was dissolved in 100 % acetic acid and freeze dried. The crude peptide was purified
by semi-preparative RP-HPLC followed by counter ion exchange of TFA to chloride using
pyridinium hydrochloride prior cyclization. The semi-protected linear peptide was cyclized in
DMF at 0.2 mg/mL peptide concentration in the presence of BOP/HOBt/DIEA (6:6:12 equiv
to the peptide) reagents at RT for 24 h. The solvent was evaporated and the remaining oily
product was dissolved in eluent A and purified by RP-HPLC. After lyophilization the purified
product was dried further in dessiccator over P2O5 and then the ClZ group from the side chain
of Lys residue was removed with liquid HF (HF – p-cresol = 10 mL : 1 g). The crude product
was purified by semi-preparative RP-HPLC and analyzed by analytical HPLC, as described
below. Identification was performed with ESI-MS (Esquire 3000+ ion trap mass spectrometer
Bruker Daltonics, Bremen, Germany).
82.3. Conjugation reaction of c[KNGRE]-NH2 peptide with p-SCN-Bn-NOTA
11.7 mg (20 µmol) from the cyclic pentapeptide c[KNGRE]-NH2 was dissolved in 0.9 mL of
0.1 M sodium carbonate buffer (pH 9.5). 12.3 mg (22 µmol) of p-SCN-Bn-NOTA
(Macrocycles Inc., Dallas, TX, USA) was dissolved in 0.1 mL DMSO, and was introduced to
the aqueous phase. The mixture was stirred for 2 h at room temperature. The resulting NOTA-
conjugated NGR analogue (NOTA-c(NGR)) was purified by means of semi-preparative RP-
HPLC and the collected fractions were lyophilized. The pure product was characterized by
analytical RP-HPLC (as described below) and ESI-MS (Shimadzu LCMS IT-TOF Mass
Spectrometer, Shimadzu Corp., Tokyo, Japan).
2.4. Radiolabeling of NODAGA-[c(RGD)]2 with Ga-68
NODAGA-[c(RGD)]2 was purchased from ABX GmbH (Radeberg, Germany). Labeling was
done manually according to the procedure desribed by Notni et al. (2011). Briefly, 68Ga was
eluted from a SnO2-based 68Ge/68Ga-generator (iTHEMBA Labs, Cape Town, South Africa)
with 1 M HCl (aq). A fraction of 1250 µl volume containing the highest activity (≈200 MBq)
was collected and buffered with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES;
800 µL, aq, 2.7 M, pH 5.8). Then, 103 µL of a 100 µM NODAGA-[c(RGD)]2 aq. solution
was added and and the mixture was let incubate for 5 min at 95°C (pH=3.0). Afterwards, the
reaction mixture was transferred onto the surface of an Empore® C18 SD 7mm/3mL
Extraction Disc Cartridge. (The cartridge was previously activated applying a 500 µL EtOH
and then a 10 mL water wash.) After binding reacted materials from the mixture, the surface
was washed with 15 mL water and then retained activity was eluted with 500 µL EtOH/0.9 %
NaCl (1:1) – solution. From the eluate, EtOH-content was evaporated in approx. 5 min under
60 mL/min He flow and at 95°C. Final volume was completed to 250 µL with water in order
to gain an isotonic final product for further use. Radiochemical purity (%) of the final product
was determined by applying an HPLC method described below.
2.5. Radiolabeling of NOTA-c(NGR) with Ga-68
This labeling protocol is based on the procedure desribed by Wängler et al. (2011). Previously
mentioned 68Ge/68Ga-generator was eluted with 1 M HCl (aq). A fraction of 1 mL volume
containing the highest activity (≈160 MBq) was collected, buffered with sodium-acetate (1M;
91 mL, aq.) and the pH of the stock solution was adjusted to ~ 4.5 by the addition of sodium-
hydroxide (10 %, 0.2 mL, aq.). Then, 15 µL of a 1 mM NOTA-c(NGR) aq. solution was
added and the mixture was let incubate for 5 min at room temperature. Afterwards, the
reaction mixture was transferred dropwise onto the surface of a pre-activated Empore® C18
SD 7mm/3mL Extraction Disc Cartridge. After binding reacted materials from the mixture,
the surface was washed with 5 mL water and then retained activity was eluted with 0.35 mL
EtOH. From the eluate, solvent was evaporated to dryness in approx. 5 min under 60 mL/min
He flow. The labeled peptide was re-dissolved in 250 µL with isotonic saline solution for
further use. Radiochemical purity (%) of the final product was determined by applying an
HPLC method described below.
2.6. Reversed Phase High Performance Liquid Chromatography (RP-HPLC) methods
For the synthesis of c[KNGRE]-NH2 peptide, the crude products and the conjugates were
purified on a KNAUER 2501 HPLC system (KNAUER, Bad Homburg, Germany) using a
semi-preparative Phenomenex Luna C18 column (250 mm x 10 mm) with 10 μm silica (100
Å pore size) (Phenomenex Inc., Torrance, CA, USA). Linear gradient elution (0 min 5 % B; 5
min 5 % B; 50 min 50 % B) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in
MeCN-H2O (80:20, v/v)) was used at a flow rate of 4 mL/min. Peaks were detected at 220
nm. In this case, analytical RP-HPLC was performed on the same instrument using a
Phenomenex Luna C18 column (250 mm x 4.6 mm) with 5 μm silica (100Å pore size) as a
stationary phase. Linear gradient elution (0 min 0 % B; 5 min 0 % B; 50 min 90 % B) using
the same eluents was applied at a flow rate of 1 mL/min. Peaks were detected at 214 nm.
The purification of the NOTA-conjugated NGR analogue was performed on a KNAUER
HPLC system using a semi-preparative Supelco Discovery® Bio Wide Pore C18 column (150
mm x 10 mm) with 10 μm silica with a flow rate 4 mL/min. After a short isocratic period (3
min) a linear gradient was used (3 min 5 % B; 25 min 65 % B) with eluent A (0.1% TFA in
water) and eluent B (0.1% TFA in MeCN-H2O (95:5, v/v), applying 254 nm for peak
detection.
For the quality control of the radiolabeled peptides, in comparison with the NOTA-c(NGR)
conjugate purification, a similar configuration and the same eluents were used on the
previously mentioned KNAUER HPLC system with an analytical Supelco Discovery® Bio
Wide Pore C18 column (250 mm x 4.6 mm) with 10 μm silica and 1.2 mL/min flow rate, with
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a gradient profile: 0 min 0% B, 3 min 0 % B; 14 min 40 % B. Signals were simultaneously
detected by radiodetector and UV detector (254 nm).
2.7. Determination of partition coefficient of 68Ga-NOTA-c(NGR)
The partition coefficient of 68Ga-NOTA-c(NGR) was expressed as logP by measuring the
distribution of radioactivity in 1-octanol and PBS-solution. Approximately 1.5 MBq of 68Ga-
NOTA-c(NGR) in 10 µL aq. solution was added to an Eppendorf-vial containing 0.5 mL of
PBS (pH = 7.4) and 0.5 mL of 1-octanol. After vortexing the mixture for 20 min vigorously,
the vial was centrifuged at 20,000 rpm for 5 min in order to reach complete separation of
layers. 100 µL of each layer was pipette into test tubes; the radioactivity was measured with a
gamma counter (Perkin-Elmer Packard Cobra, Waltham, MA, USA). LogP value was
determined from the results of six experiments.
2.8. Determination of in vitro stability of 68Ga-NOTA-c(NGR)
The stability of 68Ga-NOTA-c(NGR) was tested in PBS at 95ºC and in rat serum at 37ºC.
Approximately 8 MBq of 68Ga-NOTA-c(NGR) was pipetted into 0.5 mL PBS or into rat
serum and was incubated at the respective temperature. For 95ºC study, an aliquot of the
solution was directly transferred to reversed-phase HPLC testing (as described above) for the
determination of radiochemical purity at various time points (0, 5, 30 and 60 min). For rat
serum stability study, at various time points (0, 30, 60, 90 and 120 min) a 50 µL aliquot of the
stock solution was mixed with 50 µL cold abs. EtOH. Precipitated fraction was separated by
centrifugation at 20,000 rpm for 5 min. The supernatant was collected, further diluted with
water and transferred to reversed-phase HPLC testing (as method prescribed above) for the
determination of radiochemical purity.
2.9. Animals
Animals (Fischer-344 rats) were housed under conventional conditions in air conditioned
rooms at a temperature of 26±2°C, with 50±10% humidity and artificial lighting with a
circadian cycle of 12 h. The semi-synthetic diet (Charles River Hungary Ltd., Gödöllő,
Hungary) and drinking water were available ad libitum to all the animals. The animals
received human care complying with the criteria outlined in the “Guidelines for the welfare
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and use of animals in cancer research” (Workman et al., 1988), authorized by the Ethical
Committee for Animal Research, University of Debrecen, Hungary (permission number:
22/2007). Laboratory animals were kept and treated in compliance with all applicable sections
of the Hungarian Laws No. XXVIII/1998 and LXVII/2002 on the protection and welfare of
animals and animal welfare directions and regulations of the European Union.
2.10. Experimental tumor
Chemically induced rat mesenchymal mesoblastic nephroma (NeDe) tumor was used in our
experiments (Trencsenyi et al., 2009; Rozsa et al., 2009). The experimental renal tumor was
isolated from Fischer 344 rats which had been treated at newborn age by the i.p. injection of
125 µg/animal N-nitrosodimethylamine in saline. Tumors were removed 5–7 months after
chemical tumorogenesis, minced into smaller pieces, then the tumor slices were frozen (Dezso
et al., 1991) and the NeDe cell line was established (Rozsa et al., 2009).
2.11. Tumor models
Adult male Fischer-344 rats (n=20) weighing 200–250 g were used for tumor-transplanted
animal experiments. For the subcutaneous animal model 5x106 NeDe tumor cells in 150 µl
saline were injected subcutaneously into the left thighs. Tumor growth was assessed by
caliper measurements and tumor size was calculated using the following formula: (largest
diameter x smallest diameter2)/2. The in vivo experiments were carried out 12±2 days after
subcutaneous injection of tumor cells when the tumor volume was 1.5±0.24 cm3. For the
induction of another tumor model the subrenal capsule assay (SRCA) was used. The aim of
this surgical operation was to place Gelaspon® discs (Germed, Rudolstadt, Germany)
containing tumor cells under the capsule of the left kidney. For this transplantation, 5x106
NeDe tumor cells in 20 µl saline were placed on a Gelaspon® disc (Trencsenyi et al., 2009).
Animals were anaesthetized by 3% isoflurane with a dedicated small animal anesthesia device
and the retroperitoneum was opened by abdominal section, the left kidney was exposed and
the Gelaspon® disc containing tumor cells was placed under the renal capsule. Stitches were
put in the wound and the tumors were allowed to grow until 1.4-1.6 cm3 and in vivo
experiments were carried out.
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2.12. Small animal PET imaging using radiopharmaceuticals
12±2 days after the implantation of NeDe cells control and tumor-bearing rats were injected
via the tail vein with 7.4±0.2 MBq of 68Ga-NOTA-c(NGR) or 68Ga-NODAGA-[c(RGD)]2. 90
min after tracer injection animals were anaesthetized by 3% isoflurane with a dedicated small
animal anesthesia device and whole body PET scans (10-min static PET scans at each bed
position) were acquired using the MiniPET-II small animal PET scanner (Lajtos et al., 2013).
The MiniPET-II scanner consists of 12 detector modules including LYSO scintillator crystal
blocks and position sensitive PMTs. Each crystal block comprises 35 x 35 pins of 1.27 x 1.27
x 12 mm size. Detector signals are processed by FPGA based digital signal processing boards
with embedded Linux operating system. Data collection and image reconstruction are
performed using a data acquisition module with Ethernet communication facility and a
computer cluster of commercial PCs.  Scanner normalization and random correction were
applied on the data and the images were reconstructed with the standard EM iterative
algorithm. The pixel size was 0.5x0.5x0.5 mm and the spatial resolution varies between 1.4 to
2.1 mm from central to 25 mm radial distances. The system sensitivity is 11.4%. For the
determination of the anatomical localization of the tumors, CBCT (3D Accuitomo, XYZ Slice
View Tomograph, I. Morita MFG. Corp, Kyoto, Japan) was used. The X-ray tube settings
were voltage 60 kVp, current 8.0 µA, and exposure time 30.8 s per projection; voxel size:
160 µm.
2.13. PET data analysis
Radiotracer uptake was expressed in terms of standardized uptake values (SUVs) and tumor
to muscle (T/M) ratios. Ellipsoidal 3-dimensional volumes of interest (VOI) were manually
drawn around the edge of the tumor activity by visual inspection using BrainCad software
(http:/www.minipetct.hu). The standardized uptake value (SUV) was calculated as follows:
SUV = [ROI activity (Bq/mL)]/[injected activity (Bq)/animal weight (g)], assuming a density
of 1 g/mL. The T/M ratios were computed as the ratio between the activity in the tumor VOI
and in the background (muscle) VOI.
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2.14. Ex vivo organ distribution studies
One day after PET scans, control and tumor-bearing experimental animals were anaesthetized
and 7.4±0.2 MBq of 68Ga-NOTA-c(NGR) (approx. 1.9 µg peptide/animal) or 68Ga-
NODAGA-[c(RGD)]2 (approx. 3 µg peptide/animal) were injected via the tail vein. After the
incubation time (90 min) rats were euthanized with the intraperitoneal injection of 60 mg/kg
pentobarbital (Nembutal) and blood samples were taken from the heart. Three tissue samples
were taken from each organ (liver, spleen, kidneys, intestine, heart, stomach, muscle, lung and
tumor) and their activities were measured with a calibrated gamma counter (Perkin-Elmer
Packard Cobra, Waltham, MA, USA). The weight and the radioactivity of the samples were
used to determine the differential absorption ratio (DAR). DAR value was calculated as:
(accumulated radioactivity/g tissue)
DAR = ————————————————
(total injected radioactivity/body weight)
2.15. Blocking experiments
For the ex vivo and in vivo blocking experiments, control and NeDe tumor-bearing rats were
pretreated with 200 μg unlabeled NOTA-c(NGR) in 100 μL saline (as a blockade, approx. 100
fold of the 68Ga-labeled peptides) by intravenous injection 5 minutes prior to administration of
68Ga-NOTA-c(NGR). 90 min after the injection of the 68Ga-labeled tracer ex vivo and in vivo
biodistribution studies were performed as described above.
2.16. Western blot analysis
Cells were harvested in lysis buffer (20 mM Tris-HCl, pH 7.4, 5 mM EGTA, 1 mM 4-(2-
aminoethyl)benzensulfonyl fluoride, protease inhibitor cocktail diluted 1:100, while frozen
tissue samples were pulverized under liquid nitrogen with a mortar and pestle and the
resulting powder was subsequently dissolved in the lysis buffer mentioned above. After
sonication the protein content of the resulting samples was determined by a modified BCA
protein assay (Pierce Protein Biology Products, Thermo Fisher Scientific Inc., Rockford, IL,
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USA). The samples were then subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (10% gels were loaded with equal [20-60 μg] amount of protein per lane),
transferred to BioBond nitrocellulose membranes (Whatman, GE Healthcare Bio-Sciences
AB, Uppsala, Sweden), and then probed with mouse-anti-rat CD13 (from Santa-Cruz
Biotechnology Inc. (Dallas, TX, USA); 1:100 dilution in 5% milk containing PBS). As
secondary antibodies, horseradish peroxidase-conjugated mouse IgG Fc segment-specific
antibodies (developed in goat, 1:1000, Bio-Rad Laboratories, Inc. (Hercules, CA, USA) was
used, and the immunoreactive bands were visualized by a SuperSignal® West Pico
Chemiluminescent Substrate enhanced chemiluminescence kit (Pierce Protein Biology
Products) using a KODAK Gel Logic 1500 Imaging System (Eastman Kodak Company,
Rochester, NY, USA). To assess equal loading, when indicated, membranes were re-probed
with anti-β-actin antibodies (1:1000 dilution in 5% milk containing PBS) and visualized as
described above.
2.17. Statistical analysis
Data are presented as mean ± SD of at least three independent experiments. The significance




3.1. Chemical and radiochemical synthesis
First synthetic steps of the targeting peptide were performed successfully with a 49%
calculated cyclization yield and an almost quantitative protecting group cleavage. Purity of
the final NGR analogue (c[KNGRE]-NH2) was found to be 98%< by means of analytical
HPLC and was identified to be [M+2H]2+ = 292.9 and [M+H]+ = 584.4 by ESI-MS. Similarly,
the resulting product of the conjugation reaction of p-SCN-Bn-NOTA and c[KNGRE]-NH2
(isolated yield: 73%) was analyzed by analytical HPLC (purity 98%<), while the
identification by ESI-MS found it [M+2H]2+ = 517.75, as expected. Reaction scheme of the
chemical synthesis of NOTA-c(NGR) can be seen on Fig. 1A. Labeling procedures of NOTA-
c(NGR) and commercially available NODAGA-[c(RGD)]2 was performed in 30 min with a
decay-corrected yield in the range of 65-75 %, a radiochemical purity of 95%< and a specific
activity of 5.13 – 5.92 GBq/µmol for 68Ga-NOTA-c(NGR) and 9.34 – 10.77 GBq/µmol for
68Ga-NODAGA-[c(RGD)]2 at all cases. All labeled tracers were used directly for further
experiments after formulation. The chemical structure of 68Ga-NODAGA-[c(RGD)]2 and
newly synthesized 68Ga-NOTA-c(NGR) can be seen on Fig. 1B and C.
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Fig. 1. Reaction scheme of the chemical synthesis of NOTA-c(NGR) (A), chemical structure
of 68Ga-NOTA-c(NGR) (B) and 68Ga-NODAGA-[c(RGD)]2 (C).
3.2. Partition coefficient and in vitro stability of 68Ga-NOTA-c(NGR)
The partition coefficient (logP) of 68Ga-NOTA-c(NGR) was determined to be – 2.77 ± 0.12,
suggesting that the radiotracer is highly hydrophilic. Also, stability of the labeled peptide was
measured in rat serum at 37ºC and at increased temperature (PBS; pH = 7.4; T = 95ºC) by
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means of analytical radio-HPLC. After 2 hours of incubation in rat serum, more than 95 % of
the original labeled peptide was found to be intact; also at increased temperature first signs of
degradation was observed only at 1 hour, when still 98%< radiochemical purity was found.
These latter results suggest a highly stable molecule under the applied conditions in the
following experiments.
3.3. In vivo and ex vivo biodistribution studies on healthy animals
In vivo and ex vivo biodistribution studies were performed using healthy Fischer-344 rats as
controls. 90 min after the injection of 7.4±0.2 MBq of 68Ga-NOTA-c(NGR) or 68Ga-
NODAGA-[c(RGD)]2 the biodistributions were evaluated by whole body miniPET scans. The
representative decay-corrected coronal miniPET/CT images are shown in Fig. 2A. In the
animals injected with 68Ga-NODAGA-[c(RGD)]2 the high uptake of the liver, spleen and
intestines were clearly visualized. In contrast, moderate accumulation was observed in the
animals injected with 68Ga-NOTA-c(NGR) Fig. 2B.
This in vivo biodistribution results correlated well with the ex vivo data. For the ex vivo
studies the animals were sacrificed 90 min after the tracer injection, dissected, and the
accumulated activity of the tissues and organs was counted with a gamma counter. The results
are summarized in Fig. 2C; 90 min after the injection of 68Ga-NOTA-c(NGR) the DAR values
of kidneys and urine showed high tracer accumulation in control rats. In contrast with these
result, the liver, intestines, spleen and stomach showed significantly higher (p≤0.01) uptake
after the injection of 68Ga-NODAGA-[c(RGD)]2.
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Fig. 2. Comparison of in vivo and ex vivo biodistribution data for 68Ga-NOTA-c(NGR) (n=5)
and 68Ga-NODAGA-[c(RGD)]2 (n=5). A: Representative coronal miniPET/CT image of
control F-344 rats 90 min after the injection of 68Ga-NODAGA-[c(RGD)]2. B: Representative
coronal miniPET/CT image of control F-344 rats 90 min after the injection of 68Ga-NOTA-
c(NGR). Red arrows: liver, white arrows: urine, black arrow: intestines. C: quantitative
analysis of tracer uptake in control animals 90 min after the injection of 68Ga-NOTA-c(NGR)
and 68Ga-NODAGA-[c(RGD)]2. DAR values are presented as mean±SD; significance level:
p≤0.01 (*).
Ex vivo blocking studies were performed on healthy animals as described in Materials and
methods (see 2.15. Blocking experiments). Results are summarized in Table 1, where the DAR
values of the examined organs can be seen. The 68Ga-NOTA-c(NGR) uptake of the organs or
tissues was lower after the injection of 200 µg unlabeled NOTA-c(NGR). The radiotracer
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uptake in the selected organs was approximately two-fold higher without the blockade (Table
1).
Table 1
Tracer uptake (DAR) in selected organs/tissues 90 min after tracer injection
3.4. In vivo and ex vivo biodistribution studies on subcutan tumor model
The tumor targeting efficacy of 68Ga-NOTA-c(NGR) and 68Ga-NODAGA-[c(RGD)]2 in
NeDe tumor-bearing F-344 rats was compared by miniPET scans 90 min after tracer
injection. Representative decay-corrected axial images are shown in Fig. 3. The
subcutaneously growing NeDe tumors were clearly visualized with 68Ga-NOTA-c(NGR) (Fig.
3B) with high tumor-to-muscle (T/M) ratios (Fig. 3C), where the T/M SUVmean, and the
T/M SUVmax were 12.25±3.08 and 16.28±2.48, respectively. These ratios approximately
two-fold higher than that of the 68Ga-NODAGA-[c(RGD)]2 uptake, where the T/M SUVmean






blood 0.17  ± 0.08 0.12 ± 0.2
liver 0.21 ± 0.05 0.10 ± 0.01
spleen 0.13 ± 0.04 0.08 ± 0.01
kidney 2.02 ± 0.13 1.39 ± 0.04
large intestine 0.14 ± 0.01 0.07 ± 0.01
small intestine 0.10 ± 0.02 0.04 ± 0.02
stomach 0.17 ± 0.04 0.05 ± 0.02
muscle 0.05 ± 0.02 0.02 ± 0.01
fat 0.04 ± 0.01 0.02 ± 0.01
lung 0.24 ± 0.03 0.10 ± 0.04
heart 0.10 ± 0.01 0.04 ± 0.02
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Fig. 3. Comparison of in vivo biodistribution of 68Ga-NODAGA-[c(RGD)]2 and 68Ga-NOTA-
c(NGR) 12±2 days after subcutaneous injection of NeDe cells. Representative axial
miniPET/CT images of the same subcutaneously growing NeDe tumors (red arrows) 90 min
after the injection of 68Ga-NODAGA-[c(RGD)]2 (A) and 68Ga-NOTA-c(NGR) (B). C:
quantitative analysis of the tracer uptake in NeDe tumors (n=6). Significance level: p≤0.01
(*).
To investigate the Aminopeptidase N (APN/CD13) specificity of 68Ga-NOTA-c(NGR) in
subcutaneously growing NeDe tumors, we performed in vivo biodistribution studies at 90 min
post injection with or without a blocking dose of 200 µg unlabeled NOTA-c(NGR). Fig. 4
demonstrates that the unlabeled NOTA-c(NGR) significantly (p≤0.01) reduced the uptake of
68Ga-NOTA-c(NGR) in NeDe tumors (Fig. 4B and C). By taking the SUV values, the
SUVmean, SUVmax, T/M SUVmean and T/M SUVmax the tracer accumulation in the
tumors was blocked efficiently and dropped to 0.35±0.22, 2.26±0.43, 2.50±0.39 and
2.48±1.14, respectively, confirming the CD13 binding specificity in vivo.
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Fig. 4. Upper row: Representative axial miniPET images of the same NeDe tumor 90 min
after the injection of 68Ga-NOTA-c(NGR) and 12 days after subcutaneous injection of NeDe
cells. A: base, B: blocked (see 2.15. Materials and methods). Red arrows: tumor. C:
Quantitative analysis of in vivo tracer uptake data (90 min post inj.) in s.c. NeDe tumors for
68Ga-NOTA-c(NGR) (n=5) in comparison with data obtained for 68Ga-NOTA-c(NGR)
blocking (n=6) experiments 12±2 days after subcutaneous injection of tumor cells.
Significance level: p≤0.01 (*).
These miniPET results correlated with the ex vivo bidistribution data where the s.c. NeDe
tumor-bearing rats were sacrificed 90 min after the tracer injection, dissected, and the
accumulated activity of the tumors and muscle (as background) was counted with a gamma
counter and DAR values were calculated. The results are summarized in Table. 2.
Table 2







NeDe tumor (s.c.) 0.34 ± 0.08 0.37 ± 0.08 0.07 ± 0.02
Tumor/muscle 3.66 ± 1.23 7.42 ± 2.27 1.23 ± 0.06
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3.5. In vivo and ex vivo biodistribution studies on the SRCA tumor model
The accumulation of 68Ga-NOTA-c(NGR) and 68Ga-NODAGA-[c(RGD)]2 in NeDe tumors
growing under the left renal capsule was compared by miniPET scans 90 min after tracer
injection. Decay-corrected representative coronal images are shown in Fig. 5. NeDe tumors
growing under the renal capsule were clearly visualized with both radiotracers (Fig. 5A and
B). No significant differences (at p≤0.05 level) were found in the SUV mean values of the
tumors: SUVmean of 68Ga-NOTA-c(NGR) and 68Ga-NODAGA-[c(RGD)]2 was 1.73±0.39
and  1.31±0.24, respectively. However, significant differences (p≤0.01) were found when
SUVmax and T/M SUVmax values were compared (Fig. 5C), where the SUVmax and the
T/M SUVmax values of 68Ga-NOTA-c(NGR) uptake were 11.47±1.37 and 12.47±2.19,
respectively. These values approximately two-fold higher than that of the 68Ga-NODAGA-
[c(RGD)]2 uptake, where the SUVmax and the T/M SUVmax were 4.96±0.47 and 6.98±0.55,
respectively.
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Fig. 5. Comparison of in vivo biodistribution of 68Ga-NODAGA-[c(RGD)]2 and 68Ga-NOTA-
c(NGR) 12±2 days after SRCA implantation of NeDe cells. Representative coronal CT and
miniPET/CT images of NeDe tumors growing under the renal capsule (red arrows) 90 min
after the injection of 68Ga-NODAGA-[c(RGD)]2 (A) and 68Ga-NOTA-c(NGR) (B). C:
quantitative analysis of the tracer uptake in NeDe tumors (n=6).
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The CD13 specificity of 68Ga-NOTA-c(NGR) was also investigated in NeDe tumors growing
under the renal capsule. For the blocking experiments we performed in vivo miniPET
scanning at 90 min post injection with or without a blocking dose of 200 µg unlabeled
NOTA-c(NGR), afterwards CT scans were carried out in the same bed position. As can be
seen in Fig. 6, the unlabeled NOTA-c(NGR) reduced the uptake of 68Ga-NOTA-c(NGR) in
experimental NeDe tumors (Fig. 6B and C). The quantitative analysis of miniPET images
(Fig. 6C) showed that the SUV values significantly (p≤0.01) decreased (SUVmean:
0.63±0.22, SUVmax: 2.8±0.42, T/M SUVmean: 1.71±0.24 and T/M SUVmax: 1.96±0.56)
after the injection of unlabeled NOTA-c(NGR), that signed that the tracer accumulation in the
tumors was blocked efficiently confirming the CD13 binding specificity.
25
Fig. 6. Representative coronal CT and miniPET/CT images of the same NeDe tumor 90 min
after the injection of 68Ga-NOTA-c(NGR) and 12 days after SRCA implantation of NeDe
cells. A: base, B: blocked (see 2.15. Materials and methods). Red arrows: tumors (SRCA). C:
Quantitative analysis of in vivo tracer uptake data (90 min post inj.) in NeDe tumors for 68Ga-
NOTA-c(NGR) (n=5) in comparison with data obtained for 68Ga-NOTA-c(NGR) blocking
(n=6) experiments. Significance level: p≤0.01 (*). SRCA: Subrenal Capsule Assay.
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The ex vivo biodistribution data of the subrenal NeDe tumor bearing rats are summarized in
Table 3. Rats were sacrificed 90 min after the tracer injection, dissected and the accumulated
activity of the tumors and muscle (as background) was counted with a gamma counter and
DAR values were calculated.
Table 3
Tracer uptake (DAR) in SRCA NeDe tumors 90 min after tracer injection
3.6. In vivo and ex vivo biodistribution studies on metastases
Two weeks after NeDe cell implantation under the left renal capsule metastatic lymph nodes
were found in the tumor bearing rats. By autopsy we found that the mesenteric lymph nodes
in the abdomen and the parathymic lymph nodes in the thorax showed tumorous infiltration
(Fig. 7). The CD13 expression of the metastatic lymph nodes was confirmed by western blot
analysis (Fig. 8). The accumulation of 68Ga-NOTA-c(NGR) in the metastatic lymph nodes
was investigated by ex vivo biodistribution studies after 90 min incubation time. For the
blocking experiments 200 µg unlabeled NOTA-c(NGR) was used. By calculating the DAR
values we found high 68Ga-NOTA-c(NGR) uptake in the metastatic mesenteric (0.30 ± 0.18)
and in the parathymic (0.69 ± 0.24) lymph nodes. In blocking experiments when unlabeled
NOTA-c(NGR) was injected 5 min before the 68Ga-labeled radiotracer, the accumulation in







NeDe tumor (SRCA) 0.54 ± 0.08 0.63 ± 0.18 0.18 ± 0.06
Tumor/muscle 4.39 ± 0.46 6.49 ± 0.21 1.7 ± 0.22
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Fig. 7. Assessment of 68Ga-NOTA-c(NGR) uptake in metastatic lymph nodes 12 days after
SRCA implantation. A: control parathymic lymph node in the thorax (black arrow), B:
metastatic parathymic lymph node (blue arrow), C: metastatic mesenteric lymph nodes (white
arrows), D: representative axial miniPET image of a NeDe tumor-bearing rat 90 min after the
injection of 68Ga-NOTA-c(NGR) and 12 days after SRCA implantation of NeDe cells (red
arrow: primary NeDe tumor, gray arrow: right kidney, white arrow: metastatic mesenteric
lymph node), E: Quantitative analysis of ex vivo tracer uptake data (90 min post inj.) in NeDe
tumors for 68Ga-NOTA-c(NGR) (n=5) in comparison with data obtained for 68Ga-NOTA-
c(NGR) blocking (n=6) experiments (see Materials and methods). Significance level: p≤0.01
(*). SRCA: Subrenal Capsule Assay.
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Fig. 8. Western blot analysis of APN/CD13 expression in experimental kidney tumors and
lymph node metastases. Rat kidney was used as positive control. SRCA: Subrenal Capsule
Assay induced tumor; s.c.: subcutan tumor; Mesen. lymph node: Mesenteric lymph node
metastasis; Parath. lymph node: Parathymic lymph node metastasis.
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4. Discussion
Nowadays, the PET and SPECT imaging of tumor neoangiogenesis with isotope labeled
tracers targeting Aminopeptidase N (APN/CD13) and integrin receptors is an intensively
investigated field in oncology (Faintuch et al., 2014; Ma et al., 2013, 2014). In this paper, we
focused on the PET imaging of APN/CD13 receptor expression in experimental rat tumor
models using a new 68Ga labeled radiotracer NOTA-c(NGR).
APN/CD13 is a membrane-associated exopeptidase, involved in the angiogenesis and
metastatic process by degradation of extracellular matrix (Su et al., 2012), furthermore, one of
the promising tumor associated targets for imaging of cancer and tumor vasculature. In
addition, APN/CD13 is a promising target in anti-angiogenic therapy (Yang et al., 2014).
The asparaginyl–glycinyl–arginine (NGR) peptide has been identified as the specific ligand of
Aminopeptidase N and has a higher efficacy for the detection of neoangiogenic vessels than
the integrin receptor specific RGD peptides (Arap et al., 1998). Several studies have reported
that labeling NGR peptide with PET (64Cu, 68Ga) and SPECT (99mTc) isotopes served useful
radiotracers for the in vivo imaging of APN receptor expression of tumors and neovasculature
by binding to APN (Zhang et al., 2014; Shao et al., 2014b; Ma et al., 2013, 2014).
This current study aimed to investigate newly synthesized 68Ga-NOTA-c(NGR) as a new
molecular probe for the evaluation of APN expression in experimental tumors.
The synthesis of the cyclic NGR peptide (c[KNGRE]-NH2) was developed by Negussie et al.
(2010). They prepared the cyclic peptide using on resin cyclization. In this manuscript, we
introduced an efficient alternative route for the synthesis of c[KNGRE]-NH2 cyclic peptide. In
this case, the linear protected peptide (Boc-Lys(ClZ)-Asn(Trt)-Gly-Arg(Pbf)-Glu(OtBu)-R)
was built up on solid support by standard Fmoc/tBu strategy followed by removal of a semi-
protected peptide (H-Lys(ClZ)-Asn-Gly-Arg-Glu-NH2) from the resin using TFA cleavage
mixture. The amide bond formation between the N-terminal amino group and the -carboxyl
group of glutamic acid was carried out in diluted DMF solution by the aid of coupling agents.
Prior to the removal of ClZ protecting group with liquid HF, the semi-protected cyclic peptide
was purified by RP-HPLC. The cyclic NGR peptide was prepared successfully by the
application of this procedure and no deamidation through succinimide ring closure was
observed in any stage of the synthesis. As a following step, pure c[KNGRE]-NH2 peptide was
successfully conjugated with p-SCN-Bn-NOTA, then the resulting NOTA-c(NGR) was easily
labeled afterwards with 68Ga with a RCP of 95%< and a specific activity of 5.13 –
5.92 GBq/µmol with a protocol based on the labeling procedure described by Wängler et al.
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(2011). Similarly, the radiosynthesis of 68Ga-NODAGA-[c(RGD)]2was performed for control
experiments with a labeling procedure based on the description of Notni et al. (2011).
The in vitro experiments demonstrated that newly synthesized 68Ga-NOTA-c(NGR) is highly
hydrophilic (logP = – 2.77 ± 0.12) and was also found to be stable both in PBS at increased
temperature (T = 95ºC) for 1 hour and in rat serum at 37°C for 2 h; these results demonstrate
that 68Ga-NOTA-c(NGR) is an appropriate candidate for further experiments.
Ex vivo and in vivo biodistribution studies on control animals revealed that 68Ga-NOTA-
c(NGR) was mainly excreted from the kidney, due to its hydrophilic properties that has been
proved by the partition coefficient. On the other hand, the uptake of the tracer in other organs
was very low, especially in the abdomen (Fig. 2) in contrast to the 68Ga-NODAGA-
[c(RGD)]2, where the abdominal organs (liver, spleen, intestines) showed radiotracer uptake
after 90 min incubation time (Fig. 2). This moderate accumulation of 68Ga-NODAGA-
[c(RGD)]2 in the abdominal organs correlated well with other studies, where the
biodistribution of 68Ga-DOTA-NGR (Zhang et al., 2014) and 68Ga-NOTA-NGR (Shao et al.,
2014a, 2014b) molecules were investigated. Furthermore, the low activity of other organs also
allowed for high quality images with low background and high tumor-to-muscle ratios to be
obtained.
In our study, we investigated the tumor specific accumulation of 68Ga-NOTA-c(NGR) as a
new molecular probe for imaging angiogenesis-marker expression, comparing with the
commercially available ανβ3 integrin receptor specific 68Ga-NODAGA-[c(RGD)]2 (Pohle et
al., 2012; Beer et al., 2011) on two different animal models using a small animal PET scanner.
In this paper, we test different types of administrations of nephroblastoma (NeDe) tumor cells
to rats to investigate the expression of APN/CD13 in primary tumors. Among the
administrations, local tumor formation was induced by subcutaneous injection, and subrenal
(SRCA) implantation of NeDe tumor cell line. Comparing the two different tumor models
(SRCA versus subcutaneous), we found that the accumulation of both investigated
radiotracers in primary tumors was higher in the SRCA model (Table 2 and 3). This
difference stems from the site of the tumor cell implantation. The most commonly used
method for the induction of primary tumors is the subcutaneous injection of cancer cells. This
kind of transplantation is ectopic and lacking orthotopic tissue microenvironments.
Vascularization and tumor growing are more intensive when tumor cells are implanted at
orthotopic site (e.g. renal tumors into the kidney or subcapsular space), and the favorable
microenvironment of this site may promote higher expression of angiogenic markers;
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furthermore subserve tumor cell proliferation and generation of metastases (Borgstrom et al.,
2013; Kerbel 2003).
By taking the SUVmean values, the uptake of 68Ga-NOTA-c(NGR) of the primary tumors
(subcutaneously growing NeDe tumor (Fig 3) and tumor on the left kidney (Fig 5) was
relatively higher than that of the 68Ga-NODAGA-[c(RGD)]2 uptake, and this difference was
significant (p≤0.01) in the case of SUVmax and T/M ratios at 90 min p.i.. Interestingly, Shao
et al. (2014b) could not find a significant difference in T/M ratios between the applied NGR-
and RGD-based probes on HT-1080 tumors. Despite that, our results suggest that 68Ga-
NOTA-c(NGR) bears the potential to outperform even dimeric RGD-targeted tracers, which
might originate from the different structure and stability of the cyclic NGR peptide as a
homing device.
After blocking by unlabeled NOTA-c(NGR), the tumor uptake of 68Ga-NOTA-c(NGR)
reduced significantly (p≤0.01) in both primary tumors. Similarly to previously mentioned
studies with other 68Ga-labeled NGR-conjugates with human xenograft tumors (Zhang et al.,
2014; Shao et al., 2014a, 2014b), our successful blocking results suggest that 68Ga-labeled
NOTA-c(NGR) also specifically binds to the APN/CD13 receptors, which presence on NeDe
tumors and metastases was proved by western blot experiments (Fig. 8).
Angiogenesis is prerequisite in the multistep process of generating metastasis when cancer
cells spread from primary sites to distant places (Chaffer and Weinberg 2011). APN/CD13
may play a role in the invasion of cancer cells by enhancing their invasive capacity and
metastatic behavior (Fontijn et al., 2006) and by degrading the extracellular matrix to promote
malignant cell invasion (Antczak et al., 2001). Here, we used a syngenic metastasis animal
model (Trencsenyi et al., 2009) to investigate the expression of APN/CD13 by 68Ga-NOTA-
c(NGR) not only in primary tumors, but also in metastatic lymph nodes. The implantation of
NeDe tumor cells under the left kidney capsule caused tumor metastasis in the thoracal
parathymic lymph nodes (PTNs) (Trencsenyi et al., 2009, 2014) and in the mesenteric lymph
nodes. By ex vivo experiments we found APN/CD13 receptor specific accumulation of 68Ga-
NOTA-c(NGR) in metastatic lymph nodes (Fig. 7). These results suggest that 68Ga-NOTA-
c(NGR) is a promising molecular probe for the detection of metastases.
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5. Conclusion
In this study, we have synthesized 68Ga-NOTA-c(NGR) with high radiochemical purity and
stability. Due to its high selectivity and strong binding affinity to APN/CD13, favorable
biodistribution and pharmacokinetics, 68Ga-NOTA-c(NGR) might be a potential molecular
probe for the noninvasive detection of CD13/APN-positive tumors, metastases and
neovasculature.
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